Clinical Trial Search

Primary: Simulated Driving Performance in Healthy Participants as Measured by Standard Deviation of Lateral Position (SDLP) Using the Cognitive Research Corporation Driving…

Primary: Percentage of Participants With 2-year Progression Free Survival (PFS) — 71.6; 72.3 percentage of participants

Primary: Best Overall Response Rate (ORR), Based on Unconfirmed Response Assessment, as Assessed by Central Imaging Review Until 18 Weeks After the Start of Treatment — 54.0…

Primary: Number of Participants With Radial Artery Occlusion — 4; 2 Participants

Primary: Area Under the Concentration-Time Curve From Time 0 to 336 Hours (AUC0-336) Post First Dose — 49000; 49000; 51400 ug*h/ml

Primary: Temperature/Effectiveness — 179; 4; 21 Number of infant warmer uses

Primary: Weekly Incidence Rates of Any Adverse Events of Interest (AEIs) Reported Via Adverse Drug Reaction (ADR) Card, by Vaccine Group — 0.00; 0.00; 0.00; 10.10 Percentage of…

Primary: Survival — 125; 109 Participants

Primary: Percentage of Participants With at Least One Treatment-Emergent Adverse Event (TEAE), as Reported by the Participants or Participant's Caregivers or Observed by the…

Primary: Changes in Prothrombin Fragments F1+2 — 1315; 2530 pmol/L — p=0.029

Primary: Pharmacokinetics: Maximum Observed Plasma Concentration (Cmax) — 299 nanograms per milliliter (ng/mL)

Primary: 12-item Momentary Self-regulation Questionnaire — 3.0; 2.2; 1.9; 3.9 scores on a scale

Primary: Pharmacodynamics (PD): Maximal Effect Score (Emax) of Bipolar Drug Liking Visual Analog Scale (VAS) Scores — 53.0; 85.4; 68.6; 73.3 millimeter (mm)

Primary: Urinary Albumin to Creatinine Ratio (UACR) — -48.65; -15.31 Precent change

Primary: Percentage of Participants With Adjudicated Primary Composite Joint Safety Outcome — 3.9; 7.1; 1.5 percentage of participants — p=0.0123